Exact Mass: 351.1794

Exact Mass Matches: 351.1794

Found 134 metabolites which its exact mass value is equals to given mass value 351.1794, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

4,21-dehydrogeissoschizine

1H-Indolo[2,3-a]quinolizin-5-ium, 3-ethylidene-2,3,6,7,12,12b-hexahydro-2-[1-(hydroxymethylene)-2-methoxy-2-oxoethyl]-, [2S-[2α(E),3E,12bβ]]-

C21H23N2O3+ (351.1709)


An indole alkaloid that is the enol tautomer of geissoschizine, which is also dehydrogenated at the 4,21-position. 1H-Indolo[2,3-a]quinolizin-5-ium, 3-ethylidene-2,3,6,7,12,12b-hexahydro-2-[1-(hydroxymethylene)-2-methoxy-2-oxoethyl]-, [2S-[2α(E),3E,12bβ]]-. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=73385-56-5 (retrieved 2024-07-04) (CAS RN: 73385-56-5). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

   

Pirenzepine

2-[2-(4-methylpiperazin-1-yl)acetyl]-2,4,9-triazatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-10-one

C19H21N5O2 (351.1695)


An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. It is generally well tolerated by patients. [PubChem] A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents

   

4,21-Dehydrocorynantheine aldehyde

4,21-Dehydrocorynantheine aldehyde

C21H23N2O3+ (351.1709)


   

Tamibarotene

4-((5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid

C22H25NO3 (351.1834)


Tamibarotene is only found in individuals that have used or taken this drug. It is a novel synthetic retinoid for acute promyelocytic leukaemia (APL). Tamibarotene is currently approved in Japan for treatment of recurrent APL, and is undergoing clinical trials in the United States.Tamibarotene is a specific agonist for retinoic acid receptor alpha/beta with possible binding to retinoid X receptors (RXR). C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent Same as: D01418

   

4-{[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid

4-{[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid

C22H25NO3 (351.1834)


CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10139; ORIGINAL_PRECURSOR_SCAN_NO 10138 INTERNAL_ID 333; CONFIDENCE standard compound; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10139; ORIGINAL_PRECURSOR_SCAN_NO 10138 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10159; ORIGINAL_PRECURSOR_SCAN_NO 10156 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10167; ORIGINAL_PRECURSOR_SCAN_NO 10165 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10197; ORIGINAL_PRECURSOR_SCAN_NO 10194 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10187; ORIGINAL_PRECURSOR_SCAN_NO 10186 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10123; ORIGINAL_PRECURSOR_SCAN_NO 10122 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5493; ORIGINAL_PRECURSOR_SCAN_NO 5489 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5465; ORIGINAL_PRECURSOR_SCAN_NO 5461 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5482; ORIGINAL_PRECURSOR_SCAN_NO 5480 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5469; ORIGINAL_PRECURSOR_SCAN_NO 5467 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5500; ORIGINAL_PRECURSOR_SCAN_NO 5495 CONFIDENCE standard compound; INTERNAL_ID 333; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5570; ORIGINAL_PRECURSOR_SCAN_NO 5568 D009676 - Noxae > D013723 - Teratogens D000970 - Antineoplastic Agents

   

Marmeline

(Z,2Z)-N-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylpropa-2-enimidic acid

C22H25NO3 (351.1834)


Marmeline is found in fruits. Marmeline is an alkaloid from the leaves and unripe fruits of Aegle marmelos (bael

   

N-[(6R)-6-(Dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide

N-[(6R)-6-(Dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide

C21H22FN3O (351.1747)


   

4-Fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide

4-Fluoro-N-(3-(1-methyl-4-piperidinyl)-1H-indol-5-yl)benzamide

C21H22FN3O (351.1747)


   

3,4,5,6-Tetradehydroyohimbine

3,4,5,6-Tetradehydroyohimbine

C21H23N2O3 (351.1709)


   

UNII-EG79K9XQF5

UNII-EG79K9XQF5

C20H24F3NO (351.181)


   
   
   
   
   

oryzamutaic acid I

oryzamutaic acid I

C17H25N3O5 (351.1794)


   

SCHEMBL13222845

SCHEMBL13222845

C22H25NO3 (351.1834)


   

trioxo-3,16,18 conatriene-1,4,14

trioxo-3,16,18 conatriene-1,4,14

C22H25NO3 (351.1834)


   

8-Azabicyclo[3.2.1]octane-3,6-diol, 8-methyl-2-(phenylmethyl)-, 6-benzoate

8-Azabicyclo[3.2.1]octane-3,6-diol, 8-methyl-2-(phenylmethyl)-, 6-benzoate

C22H25NO3 (351.1834)


   
   
   
   
   
   
   
   
   
   
   

JWH 250 5-hydroxyindole metabolite

JWH 250 5-hydroxyindole metabolite

C22H25NO3 (351.1834)


   
   
   
   

JWH 250 N-(5-hydroxypentyl) metabolite

JWH 250 N-(5-hydroxypentyl) metabolite

C22H25NO3 (351.1834)


   
   
   
   
   

3,N4-Hydroxy-epoxyoctenal-deoxycytidine

3,N4-Hydroxy-epoxyoctenal-deoxycytidine

C17H25N3O5 (351.1794)


   
   
   
   
   
   
   
   
   
   
   

(S)-8-(2-hydroxy-2,2-diphenylacetoxy)-1-methyl-1-azoniabicyclo[2.2.2]octane

(S)-8-(2-hydroxy-2,2-diphenylacetoxy)-1-methyl-1-azoniabicyclo[2.2.2]octane

C22H25NO3 (351.1834)


   

JWH 250 N-(4-hydroxypentyl) metabolite

JWH 250 N-(4-hydroxypentyl) metabolite

C22H25NO3 (351.1834)


   

Marmeline

(2Z)-N-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylprop-2-enamide

C22H25NO3 (351.1834)


   

endo-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-2,2-diphenylacetate

endo-8-Methyl-8-azabicyclo[3.2.1]octan-3-yl 2-hydroxy-2,2-diphenylacetate

C22H25NO3 (351.1834)


   

4-(1-BOC-piperidin-4-yloxy)-2-methoxyphenylboronic acid

4-(1-BOC-piperidin-4-yloxy)-2-methoxyphenylboronic acid

C17H26BNO6 (351.1853)


   

4-(1-BOC-piperidin-4-yloxy)-3-methoxyphenylboronic acid

4-(1-BOC-piperidin-4-yloxy)-3-methoxyphenylboronic acid

C17H26BNO6 (351.1853)


   

Pipoxolan

Pipoxolan Hcl

C22H25NO3 (351.1834)


C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

   

(S)-(+)-2-DIBENZYLAMINO-3-PHENYL-1-PROPANOL

(S)-(+)-2-DIBENZYLAMINO-3-PHENYL-1-PROPANOL

C22H25NO3 (351.1834)


   

2,4,6-trip-tolyl-1,3,5-triazine

2,4,6-trip-tolyl-1,3,5-triazine

C24H21N3 (351.1735)


   

1H-​Benzimidazole-​5-​carboxylic acid, 2-​[[[4-​(aminoiminomethyl)​phenyl]​amino]​methyl]​-​1-​methyl-​, ethyl ester

1H-​Benzimidazole-​5-​carboxylic acid, 2-​[[[4-​(aminoiminomethyl)​phenyl]​amino]​methyl]​-​1-​methyl-​, ethyl ester

C19H21N5O2 (351.1695)


   

1,3,5-Tris(4-aminophenyl)benzene

1,3,5-Tris(4-aminophenyl)benzene

C24H21N3 (351.1735)


   

5-[4-(TERT-BUTYL)PHENYL]-4-(4-ISOPROPYLPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL

5-[4-(TERT-BUTYL)PHENYL]-4-(4-ISOPROPYLPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL

C21H25N3S (351.1769)


   

(1R,2S)-trans-2-(Fmoc-aminomethyl)cyclohexanol

(1R,2S)-trans-2-(Fmoc-aminomethyl)cyclohexanol

C22H25NO3 (351.1834)


   

1-TERT-BUTYL 2-METHYL 4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-PYRROLE-1,2-DICARBOXYLATE

1-TERT-BUTYL 2-METHYL 4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-PYRROLE-1,2-DICARBOXYLATE

C17H26BNO6 (351.1853)


   

Fendiline Hydrochloride

Fendiline Hydrochloride

C23H26ClN (351.1754)


D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

Devaleryl Valsartan Impurity

Devaleryl Valsartan Impurity

C19H21N5O2 (351.1695)


   

N,N,N-TRIPHENYL-1,3,5-BENZENETRIAMINE

N,N,N-TRIPHENYL-1,3,5-BENZENETRIAMINE

C24H21N3 (351.1735)


   

(1S,2R)-trans-2-(Fmoc-aminomethyl)cyclohexanol

(1S,2R)-trans-2-(Fmoc-aminomethyl)cyclohexanol

C22H25NO3 (351.1834)


   

4-(4-(4-(4-METHOXYPHENYL)PIPERAZIN-1-YL)PHENYL)-1H-1,2,4-TRIAZOL-5(4H)-ONE

4-(4-(4-(4-METHOXYPHENYL)PIPERAZIN-1-YL)PHENYL)-1H-1,2,4-TRIAZOL-5(4H)-ONE

C19H21N5O2 (351.1695)


   

LY 344864

N-[(6R)-6-(Dimethylamino)-6,7,8,9-tetrahydro-5H-carbazol-3-yl]-4-fluorobenzamide

C21H22FN3O (351.1747)


LY 344864 is a selective, orally active 5-HT1F receptor agonist with a Ki of 6 nM. LY 344864 is a full agonist producing an effect similar in magnitude to serotonin itself. LY 344864 can cross the blood brain barrier to some extent[1].

   

Saxagliptin Hydrochloride

Saxagliptin Hydrochloride

C18H26ClN3O2 (351.1713)


C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D054795 - Incretins D007004 - Hypoglycemic Agents > D054873 - Dipeptidyl-Peptidase IV Inhibitors D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor

   

3-[butyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile

3-[butyl[4-[(4-nitrophenyl)azo]phenyl]amino]propiononitrile

C19H21N5O2 (351.1695)


   

LY 334370

4-Fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide

C21H22FN3O (351.1747)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM.

   

1,3,5-Trimethyl-2,4,6-Tris(4-pyridyl)benzene

1,3,5-Trimethyl-2,4,6-Tris(4-pyridyl)benzene

C24H21N3 (351.1735)


   

GLYCYL-leucyl-tyrosine

GLYCYL-leucyl-tyrosine

C17H25N3O5 (351.1794)


   

LY 344864 racemate

LY 344864 racemate

C21H22FN3O (351.1747)


LY 344864 racemate is a 5-HT1F receptor agonist extracted from patent US 5708187 A.

   

2-methyl-3-[(2-methyl-1H-indol-3-yl)-(2-pyridinyl)methyl]-1H-indole

2-methyl-3-[(2-methyl-1H-indol-3-yl)-(2-pyridinyl)methyl]-1H-indole

C24H21N3 (351.1735)


   

8-[1-(3-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1,4-dioxa-8-azaspiro[4.5]decane

8-[1-(3-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]-1,4-dioxa-8-azaspiro[4.5]decane

C19H21N5O2 (351.1695)


   

L-Valine, L-phenylalanyl-L-seryl-

L-Valine, L-phenylalanyl-L-seryl-

C17H25N3O5 (351.1794)


   

L-Tyrosyl-L-alanyl-L-valine

L-Tyrosyl-L-alanyl-L-valine

C17H25N3O5 (351.1794)


   

D-Leucyl-N-(3-Chlorobenzyl)-L-Prolinamide

D-Leucyl-N-(3-Chlorobenzyl)-L-Prolinamide

C18H26ClN3O2 (351.1713)


   

Tamibarotene

Tamibarotene

C22H25NO3 (351.1834)


C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent

   

1H-indazol-3-yl-[2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

1H-indazol-3-yl-[2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

C19H21N5O2 (351.1695)


   
   

methyl (1S,16S,20S)-16-methyl-17-oxa-3-aza-13-azoniapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,14,18-hexaene-19-carboxylate

methyl (1S,16S,20S)-16-methyl-17-oxa-3-aza-13-azoniapentacyclo[11.8.0.02,10.04,9.015,20]henicosa-2(10),4,6,8,14,18-hexaene-19-carboxylate

C21H23N2O3+ (351.1709)


   

8-{[butyl(ethyl)amino]methyl}-7-hydroxy-4-phenyl-2H-chromen-2-one

8-{[butyl(ethyl)amino]methyl}-7-hydroxy-4-phenyl-2H-chromen-2-one

C22H25NO3 (351.1834)


   

H-Leu-Gly-Tyr-OH

H-Leu-Gly-Tyr-OH

C17H25N3O5 (351.1794)


   
   

2-(4-benzoylphenoxy)-N-(4-methylcyclohexyl)acetamide

2-(4-benzoylphenoxy)-N-(4-methylcyclohexyl)acetamide

C22H25NO3 (351.1834)


   
   

Dihydroserpentine

Dihydroserpentine

C21H23N2O3+ (351.1709)


   
   
   
   

Tyrosyl-isoleucyl-glycine

Tyrosyl-isoleucyl-glycine

C17H25N3O5 (351.1794)


   
   
   
   
   

(1S,5R)-N-(2-fluorophenyl)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

(1S,5R)-N-(2-fluorophenyl)-7-[4-[(E)-prop-1-enyl]phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide

C21H22FN3O (351.1747)


   
   
   
   
   
   
   
   
   
   
   

1H-indazol-3-yl-[(2S)-2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

1H-indazol-3-yl-[(2S)-2-[6-methyl-4-(methylamino)pyridin-2-yl]morpholin-4-yl]methanone

C19H21N5O2 (351.1695)


   

pirenzepine

pirenzepine

C19H21N5O2 (351.1695)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents

   

Am 80

Tamibarotene

C22H25NO3 (351.1834)


C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C804 - Retinoic Acid Agent C308 - Immunotherapeutic Agent > C129820 - Antineoplastic Immunomodulating Agent Same as: D01418

   

Am 580

4-{[(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid

C22H25NO3 (351.1834)


D009676 - Noxae > D013723 - Teratogens D000970 - Antineoplastic Agents

   

Dehydro-geissoschizine

Dehydro-geissoschizine

C21H23N2O3 (351.1709)


   
   
   
   
   
   

(3r,8s,11ar,11br)-5-[(3r)-3-amino-3-carboxypropyl]-8-hydroxy-1h,2h,3h,8h,9h,10h,11h,11ah,11bh-pyrido[2,1-f]1,6-naphthyridine-3-carboxylic acid

(3r,8s,11ar,11br)-5-[(3r)-3-amino-3-carboxypropyl]-8-hydroxy-1h,2h,3h,8h,9h,10h,11h,11ah,11bh-pyrido[2,1-f]1,6-naphthyridine-3-carboxylic acid

C17H25N3O5 (351.1794)


   

(2e)-n-[(2r)-2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl]-3-phenylprop-2-enimidic acid

(2e)-n-[(2r)-2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl]-3-phenylprop-2-enimidic acid

C22H25NO3 (351.1834)


   

2-hydroxy-10-methyl-4-phenyl-6-[(1e)-prop-1-en-1-yl]-6h,6ah,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one

2-hydroxy-10-methyl-4-phenyl-6-[(1e)-prop-1-en-1-yl]-6h,6ah,7h,8h,9h,10h,10ah-isochromeno[4,3-c]pyridin-1-one

C22H25NO3 (351.1834)


   

6-methyl-1-{[3-(4-methylpent-3-en-1-yl)oxiran-2-yl]methyl}-9h-carbazole-2,7-diol

6-methyl-1-{[3-(4-methylpent-3-en-1-yl)oxiran-2-yl]methyl}-9h-carbazole-2,7-diol

C22H25NO3 (351.1834)


   

(2s,3e,12bs)-3-ethylidene-2-(1-hydroxy-3-methoxy-3-oxoprop-1-en-2-yl)-1h,2h,6h,7h,12h,12bh-5λ⁵-indolo[2,3-a]quinolizin-5-ylium

(2s,3e,12bs)-3-ethylidene-2-(1-hydroxy-3-methoxy-3-oxoprop-1-en-2-yl)-1h,2h,6h,7h,12h,12bh-5λ⁵-indolo[2,3-a]quinolizin-5-ylium

[C21H23N2O3]+ (351.1709)


   

5-(3-amino-3-carboxypropyl)-8-hydroxy-1h,2h,3h,8h,9h,10h,11h,11ah,11bh-pyrido[2,1-f]1,6-naphthyridine-3-carboxylic acid

5-(3-amino-3-carboxypropyl)-8-hydroxy-1h,2h,3h,8h,9h,10h,11h,11ah,11bh-pyrido[2,1-f]1,6-naphthyridine-3-carboxylic acid

C17H25N3O5 (351.1794)


   

(2z)-n-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylprop-2-enimidic acid

(2z)-n-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylprop-2-enimidic acid

C22H25NO3 (351.1834)


   

n-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylprop-2-enimidic acid

n-(2-hydroxy-2-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}ethyl)-3-phenylprop-2-enimidic acid

C22H25NO3 (351.1834)


   

4-[(8as)-7-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]-2-methoxyphenol

4-[(8as)-7-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]-2-methoxyphenol

C22H25NO3 (351.1834)


   

(1s,2r,3r,5s,6s)-2-benzyl-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate

(1s,2r,3r,5s,6s)-2-benzyl-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate

C22H25NO3 (351.1834)


   

2-benzyl-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate

2-benzyl-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate

C22H25NO3 (351.1834)


   

4-[(8ar)-7-(3,4-dimethoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol

4-[(8ar)-7-(3,4-dimethoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol

C22H25NO3 (351.1834)


   

4-[7-(3,4-dimethoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol

4-[7-(3,4-dimethoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol

C22H25NO3 (351.1834)


   

2-methoxy-4-[7-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol

2-methoxy-4-[7-(4-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizin-6-yl]phenol

C22H25NO3 (351.1834)


   

2-[2,2-bis(1h-indol-3-yl)ethyl]aniline

2-[2,2-bis(1h-indol-3-yl)ethyl]aniline

C24H21N3 (351.1735)